- Home
- WRN vs CLLS Comparison
WRN vs CLLS Comparison
Compare WRN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRN | CLLS |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.2M | 394.4M |
| IPO Year | 2006 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WRN | CLLS |
|---|---|---|
| Price | $2.33 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.58 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 966.8K | 19.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $2.35 |
| 52 Week High | $4.26 | $5.48 |
Technical Indicators
Market Signals| Indicator | WRN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.36 | 26.01 |
| Support Level | $2.02 | N/A |
| Resistance Level | $2.34 | $2.99 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 3.75 | 8.77 |
Price Performance
Historical ComparisonAbout WRN Western Copper and Gold Corporation
Western Copper & Gold Corp is a Canada-based exploration-stage company. The company is engaged in the exploration and development of the Casino mineral property located in Yukon, Canada (the Casino Project). The Casino can deliver the critical minerals necessary for the energy transition while serving as an engine for long-term economic growth and prosperity in the North.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.